1
|
He Y, Zhang Y, Li W, Li Q, Zhao B, Tang X, Chen D, Zhang T, Zhang T, Zhong Z. Evaluating blood-brain barrier disruption and infarction volume concurrently in rats subjected to ischemic stroke using an optical imaging system. J Neurosci Methods 2022; 378:109630. [DOI: 10.1016/j.jneumeth.2022.109630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Revised: 05/16/2022] [Accepted: 05/19/2022] [Indexed: 10/18/2022]
|
2
|
Yu Z, He Y, Schomann T, Wu K, Hao Y, Suidgeest E, Zhang H, Eich C, Cruz LJ. Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaF 2 Nanoparticles. Pharmaceutics 2022; 14:840. [PMID: 35456674 PMCID: PMC9024546 DOI: 10.3390/pharmaceutics14040840] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 04/06/2022] [Accepted: 04/08/2022] [Indexed: 01/16/2023] Open
Abstract
Nowadays, cancer poses a significant hazard to humans. Limitations in early diagnosis techniques not only result in a waste of healthcare resources but can even lead to delays in diagnosis and treatment, consequently reducing cure rates. Therefore, it is crucial to develop an imaging probe that can provide diagnostic information precisely and rapidly. Here, we used a simple hydrothermal method to design a multimodal imaging probe based on the excellent properties of rare-earth ions. Calcium fluoride co-doped with ytterbium, gadolinium, and neodymium (CaF2:Y,Gd,Nd) nanoparticles (NPs) is highly crystalline, homogeneous in morphology, and displays a high biosafety profile. In addition, in vitro and ex vivo experiments explored the multimodal imaging capability of CaF2:Y,Gd,Nd and demonstrated the efficient performance of CaF2:Y,Gd,Nd during NIR-II fluorescence/photoacoustic/magnetic resonance imaging. Collectively, our novel diagnosis nanoparticle will generate new ideas for the development of multifunctional nanoplatforms for disease diagnosis and treatment.
Collapse
Affiliation(s)
- Zhenfeng Yu
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
| | - Yuanyuan He
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
| | - Timo Schomann
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
- Percuros B.V., Zernikedreef 8, 2333 CL Leiden, The Netherlands
| | - Kefan Wu
- Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands; (K.W.); (H.Z.)
| | - Yang Hao
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
| | - Ernst Suidgeest
- C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
| | - Hong Zhang
- Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands; (K.W.); (H.Z.)
| | - Christina Eich
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
| | - Luis J. Cruz
- Translational Nanobiomaterials and Imaging Group, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; (Z.Y.); (Y.H.); (T.S.); (Y.H.)
| |
Collapse
|
3
|
Wang Y, Dikeman D, Zhang J, Ackerman N, Kim S, Alphonse MP, Ortines RV, Liu H, Joyce DP, Dillen CA, Thompson JM, Thomas AA, Plaut RD, Miller LS, Archer NK. CCR2 contributes to host defense against Staphylococcus aureus orthopedic implant-associated infections in mice. J Orthop Res 2022; 40:409-419. [PMID: 33713394 PMCID: PMC8435538 DOI: 10.1002/jor.25027] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 02/19/2021] [Accepted: 03/10/2021] [Indexed: 02/04/2023]
Abstract
C-C motif chemokine receptor 2 (CCR2) is an important mediator of myeloid cell chemotaxis during inflammation and infection. Myeloid cells such as monocytes, macrophages, and neutrophils contribute to host defense during orthopedic implant-associated infections (OIAI), but whether CCR2-mediated chemotaxis is involved remains unclear. Therefore, a Staphylococcus aureus OIAI model was performed by surgically placing an orthopedic-grade titanium implant and inoculating a bioluminescent S. aureus strain in knee joints of wildtype (wt) and CCR2-deficient mice. In vivo bioluminescent signals significantly increased in CCR2-deficient mice compared with wt mice at later time points (Days 14-28), which was confirmed with ex vivo colony-forming unit enumeration. S. aureus γ-hemolysin utilizes CCR2 to induce host cell lysis. However, there were no differences in bacterial burden when the OIAI model was performed with a parental versus a mutant γ-hemolysin-deficient S. aureus strain, indicating that the protection was mediated by the host cell function of CCR2 rather than γ-hemolysin virulence. Although CCR2-deficient and wt mice had similar cellular infiltrates in the infected joint tissue, CCR2-deficient mice had reduced myeloid cells and γδ T cells in the draining lymph nodes. Taken together, CCR2 contributed to host defense at later time points during an OIAI by increasing immune cell infiltrates in the draining lymph nodes, which likely contained the infection and prevented invasive spread.
Collapse
Affiliation(s)
- Yu Wang
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Dustin Dikeman
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Jeffrey Zhang
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Nicole Ackerman
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Sophia Kim
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Martin P. Alphonse
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Roger V. Ortines
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Haiyun Liu
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Daniel P. Joyce
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - Carly A. Dillen
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| | - John M. Thompson
- Department of Orthopaedic Surgery, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA
| | - Abigail A. Thomas
- Division of Bacterial Parasitic, and Allergenic Products,
Center for Biologics Evaluation and Research, Food and Drug Administration, Silver
Spring, Maryland, USA
| | - Roger D. Plaut
- Division of Bacterial Parasitic, and Allergenic Products,
Center for Biologics Evaluation and Research, Food and Drug Administration, Silver
Spring, Maryland, USA
| | - Lloyd S. Miller
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA,Department of Immunology, Janssen Research and Development,
Spring House, Pennsylvania, USA
| | - Nathan K. Archer
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
4
|
Microbial-based cancer therapy-bugs as drugs: History & the essential role of medical imaging. Cancer Treat Res Commun 2021; 28:100436. [PMID: 34298430 DOI: 10.1016/j.ctarc.2021.100436] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 12/15/2022]
Abstract
Microbial-based cancer therapy aims to use tumor-specific infectious microbes to fulfill the unmet medical needs for patients with difficult-to-treat malignancies. The NIH is calling to revisit the old concept from new perspectives, by incorporating advances in science and technology, to establish an alternative to the traditional categories of cancer managements. Medical imaging offers unique insight into the mechanisms of action, assessment of success/failure, and advantages/pitfalls of microbial-based cancer therapy, which in turn should facilitate the advances of this new initiative in modern medical oncology.
Collapse
|
5
|
Klein K, Schweizer TA, Siwy K, Lechmann B, Karol A, von Rechenberg B, Achermann Y, Darwiche SE. Establishment of a localized acute implant-associated Staphylococcus aureus bone infection model in sheep. Pathog Dis 2021; 79:6298225. [PMID: 34124751 DOI: 10.1093/femspd/ftab032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 06/11/2021] [Indexed: 11/15/2022] Open
Abstract
Orthopedic implant-associated bacterial infections with Staphylococcus aureus constitute a major clinical problem, and large pre-clinical animal models remain scarce. The aim of this study was to establish a standardized method of a localized, acute S. aureus bone infection in the presence of complex implanted devices in a sheep model. Four sheep underwent surgery receiving a complex implanted metallic device with a component stabilizing a bone defect created in the left tibial metaphysis, and an attached component placed in adjacent soft tissue. The bone defect was inoculated with S. aureus strain ATCC25293 (1 × 104 CFU). Twenty one days later, the surgery site was macroscopically evaluated, tissue samples and implants harvested for bacterial cell count quantification and tissue samples histologically analyzed. The animals exhibited clinical signs of localized infection (e.g. swelling, lameness, pain) but did not develop symptoms of sepsis. After euthanasia, macroscopic assessment revealed a localized bone and soft tissue infection at the surgery site. Histologically, an acute inflammation with neutrophils but also signs of bone destruction with necrosis was noted. An ovine model of a localized, acute S. aureus bone infection with complex implants was successfully established and could be used to test novel treatments against orthopedic implant-associated infections.
Collapse
Affiliation(s)
- Karina Klein
- Musculoskeletal Research Unit, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Tiziano A Schweizer
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Katharina Siwy
- Musculoskeletal Research Unit, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | | | - Agnieszka Karol
- Musculoskeletal Research Unit, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Brigitte von Rechenberg
- Musculoskeletal Research Unit, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.,Competence Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland
| | - Yvonne Achermann
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.,Competence Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland
| | - Salim E Darwiche
- Musculoskeletal Research Unit, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.,Competence Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland
| |
Collapse
|
6
|
CORR Insights®: How Successful Is Antibiotic Treatment for Superficial Surgical Site Infections After Open Fracture? A Fluid Lavage of Open Wounds (FLOW) Cohort Secondary Analysis. Clin Orthop Relat Res 2020; 478:2856-2858. [PMID: 32604159 PMCID: PMC7899411 DOI: 10.1097/corr.0000000000001387] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
7
|
Wang Y, Ashbaugh AG, Dikeman DA, Zhang J, Ackerman NE, Kim SE, Falgons C, Ortines RV, Liu H, Joyce DP, Alphonse MP, Dillen CA, Thompson JM, Archer NK, Miller LS. Interleukin-1β and tumor necrosis factor are essential in controlling an experimental orthopedic implant-associated infection. J Orthop Res 2020; 38:1800-1809. [PMID: 31975434 PMCID: PMC7354231 DOI: 10.1002/jor.24608] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/15/2020] [Accepted: 01/22/2020] [Indexed: 02/04/2023]
Abstract
Orthopedic implant-associated infection (OIAI) is a major complication that leads to implant failure. In preclinical models of Staphylococcus aureus OIAI, osteomyelitis and septic arthritis, interleukin-1α (IL-1α), IL-1β, and tumor necrosis factor (TNF) are induced, but whether they have interactive or distinctive roles in host defense are unclear. Herein, a S. aureus OIAI model was performed in mice deficient in IL-1α, IL-1β, or TNF. Mice deficient in IL-1β or TNF (to a lesser extent) but not IL-1α had increased bacterial burden at the site of the OIAI throughout the 28-day experiment. IL-1β and TNF had a combined and critical role in host defense as mice deficient in both IL-1R and TNF (IL-1R/TNF-deficient mice) had a 40% mortality rate, which was associated with markedly increased bacterial burden at the site of the OIAI infection. Finally, IL-1α- and IL-1β-deficient mice had impaired neutrophil recruitment whereas IL-1β-, TNF-, and IL-1R/TNF-deficient mice all had impaired recruitment of both neutrophils and monocytes. Therefore, IL-1β and TNF contributed to host defense against S. aureus OIAI and neutrophil recruitment was primarily mediated by IL-1β and monocyte recruitment was mediated by both IL-1β and TNF.
Collapse
Affiliation(s)
- Yu Wang
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Alyssa G. Ashbaugh
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Dustin A. Dikeman
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Jeffrey Zhang
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Nicole E. Ackerman
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Sophie E. Kim
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Christian Falgons
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Roger V. Ortines
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Haiyun Liu
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Daniel P. Joyce
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Martin Prince Alphonse
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Carly A. Dillen
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - John M. Thompson
- Department of Orthopaedic Surgery, Johns Hopkins University
School of Medicine, Baltimore, MD, 21287, USA
| | - Nathan K. Archer
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA
| | - Lloyd S. Miller
- Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, MD, 21231, USA,Department of Orthopaedic Surgery, Johns Hopkins University
School of Medicine, Baltimore, MD, 21287, USA,Department of Medicine, Division of Infectious Diseases,
Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA,Department of Materials Science and Engineering, Johns
Hopkins University, Baltimore, MD, 21218, USA.,Janssen Research and Development, Spring House, PA, 19477,
USA.,Address correspondence to Lloyd S. Miller,
, Johns Hopkins Department of
Dermatology, Cancer Research Building II, Suite 205, 1550 Orleans Street,
Baltimore, MD 21231, Phone: (410) 955-8662, Fax: (410) 955-8645
| |
Collapse
|
8
|
Busscher HJ, Woudstra W, van Kooten TG, Jutte P, Shi L, Liu J, Hinrichs WLJ, Frijlink HW, Shi R, Liu J, Parvizi J, Kates S, Rotello VM, Schaer TP, Williams D, Grainger DW, van der Mei HC. Accepting higher morbidity in exchange for sacrificing fewer animals in studies developing novel infection-control strategies. Biomaterials 2019; 232:119737. [PMID: 31901693 DOI: 10.1016/j.biomaterials.2019.119737] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 12/02/2019] [Accepted: 12/25/2019] [Indexed: 10/25/2022]
Abstract
Preventing bacterial infections from becoming the leading cause of death by the year 2050 requires the development of novel, infection-control strategies, building heavily on biomaterials science, including nanotechnology. Pre-clinical (animal) studies are indispensable for this development. Often, animal infection outcomes bear little relation to human clinical outcome. Here, we review conclusions from pathogen-inoculum dose-finding pilot studies for evaluation of novel infection-control strategies in murine models. Pathogen-inoculum doses are generally preferred that produce the largest differences in quantitative infection outcome parameters between a control and an experimental group, without death or termination of animals due to having reached an inhumane end-point during the study. However, animal death may represent a better end-point for evaluation than large differences in outcome parameters or number of days over which infection persists. The clinical relevance of lower pre-clinical outcomes, such as bioluminescence, colony forming units (CFUs) retrieved or more rapid clearance of infection is unknown, as most animals cure infection without intervention, depending on pathogen-species and pathogen-inoculum dose administered. In human clinical practice, patients suffering from infection present to hospital emergency wards, frequently in life-threatening conditions. Animal infection-models should therefore use prevention of death and recurrence of infection as primary efficacy targets to be addressed by novel strategies. To compensate for increased animal morbidity and mortality, animal experiments should solely be conducted for pre-clinical proof of principle and safety. With the advent of sophisticated in vitro models, we advocate limiting use of animal models when exploring pathogenesis or infection mechanisms.
Collapse
Affiliation(s)
- Henk J Busscher
- University of Groningen, University Medical Center Groningen, Department of Biomedical Engineering, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands.
| | - Willem Woudstra
- University of Groningen, University Medical Center Groningen, Department of Biomedical Engineering, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands
| | - Theo G van Kooten
- University of Groningen, University Medical Center Groningen, Department of Biomedical Engineering, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands
| | - Paul Jutte
- University of Groningen, University Medical Center of Groningen, Department of Orthopaedic Surgery, Hanzeplein 1, 9700 RB, Groningen, the Netherlands
| | - Linqi Shi
- State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, 300071, PR China
| | - Jianfeng Liu
- Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, PR China
| | - Wouter L J Hinrichs
- University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands
| | - Hendrik W Frijlink
- University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands
| | - Rui Shi
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, 199 Ren'ai Rd, Suzhou, 215123, Jiangsu, PR China
| | - Jian Liu
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, 199 Ren'ai Rd, Suzhou, 215123, Jiangsu, PR China
| | - Javad Parvizi
- Sidney Kimmel Medical College, Rothman Institute at Thomas Jefferson University Hospital, Sheridan Building, Suite 1000, 125 South 9th Street, Philadelphia, PA, 19107, USA
| | - Stephen Kates
- Virginia Commonwealth University, Department of Orthopaedic Surgery, 1200 E. Broad St, Richmond, VA, 23059-0153, USA
| | - Vincent M Rotello
- University of Massachusetts, Department of Chemistry, 710 North Pleasant Street, Amherst, MA, 01003, USA
| | - Thomas P Schaer
- University of Pennsylvania, Department of Clinical Studies New Bolton Center, Kennett Square, PA, USA
| | - Dustin Williams
- University of Utah, Department of Orthopaedics, Salt Lake City, UT, 84112, USA; George E. Wahlen Department of Veterans Affairs, Salt Lake City, UT, 84148, USA
| | - David W Grainger
- University of Utah, Department of Biomedical Engineering, Department of Pharmaceutics and Pharmaceutical Chemistry, Salt Lake City, UT, 84112, USA
| | - Henny C van der Mei
- University of Groningen, University Medical Center Groningen, Department of Biomedical Engineering, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands.
| |
Collapse
|